Språk: en

Stayble Therapeutics AB (“Stayble” or “the Company”) announces today that the Company will participate in the investor meeting “Investera som proffsen,” organized by Financial Stockholm on September 25, 2023.

Stayble Therapeutics AB (“Stayble” or the “Company”) today announces that the Last Patient Last Visit (LPLV) in the Phase 2b clinical study in degenerative disc disease has been completed.  This means that the target number of evaluable patients in the study has now been reached twelve months after receiving treatment with STA363. The Phase 2b study, aimed at evaluating the pain relief of the drug candidate STA363, has been successfully concluded with high quality, good compliance and a low patient dropout rate. The company is following the previously communicated timeline and expects to communicate top line results in the fourth quarter of 2023.

Stayble Therapeutics AB (“Stayble” or “the Company”) announces today that the Company has terminated the agreement regarding the liquidity provider with Lago Kapital AB (“Lago”). The agreement will cease to be effective on September 29, 2023.

Stayble Therapeutics AB (“Stayble” or the “Company”) announces today that the first patient has been enrolled in the Company’s Phase 1b clinical study with STA363 for treatment of herniated discs. STA363 for Herniated discs is the second indication for the drug candidate STA363, which is also undergoing a clinical study in degenerative disc disease. Stayble has successfully completed a Phase 1b study in degenerative disc disease and is currently in the final phase of an ongoing Phase 2b study.

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its half-year report for 2023. The report is available as an attached document and on the Company’s website, www.staybletherapeutics.com/en/investors/financial-reports/. Below is a summary of the report.

Stayble Therapeutics AB (“Stayble” or the “Company”) announces that approximately 90% of all patients in the Company’s ongoing Phase IIb study in degenerative disc disease have completed their 12-month follow-up. The study remains of high quality with a low drop-out rate.

Stayble Therapeutics AB (“Stayble” or the “Company”) announces that approximately 90% of all patients in the Company’s ongoing Phase IIb study in degenerative disc disease have completed their 12-month follow-up. The study remains of high quality with a low drop-out rate.

As part of Stayble Therapeutics’ (“Stayble”) strategy to find a development partner, the company participated in the international Bio International Convention in Boston last week. During the convention, Stayble presented to several potential partners who could bring Stayble’s drug candidate to the market.

Stayble Therapeutics AB, org.nr 559024-8372 (”Bolaget”), har hållit årsstämma den 1 juni 2023 kl. 14.00 på Bolagets kontor på Arvid Hedvalls Backe 4 i Göteborg. Vid stämman fattades beslut om, bland annat, nedanstående.

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its quarterly report for the first quarter of 2023. The report is available as an attached document and on the Company’s website, www.staybletherapeutics.com/en/investors/financial-reports/. Below is a summary of the report.

Stayble Therapeutics AB (”Stayble” eller ”Bolaget”) publicerar idag årsredovisningen för 2022. Årsredovisningen finns tillgänglig på bolagets hemsida (https://staybletherapeutics.com/sv/investerare/finansiella-rapporter/) och bifogad i detta utskick.

Aktieägarna i Stayble Therapeutics AB, org.nr 559024-8372, kallas till årsstämma den 1 juni 2023 kl. 14.00 på bolagets kontor på Arvid Hedvalls Backe 4 i Göteborg. Inregistrering till årsstämman påbörjas kl. 13.30.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, RUSSIA, BELARUS OR IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION OR WOULD REQUITE FURTHER REGISTRATION OR OTHER MEASURES ABOVE WHAT IS REQUIRED BY SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.

NB: This is an English convenience translation of this press release. In case of any discrepancy, the correct version is the Swedish original “Stayble Therapeutics AB meddelar sista dag för handel med BTA”.

Stayble Therapeutics AB’s (”Stayble” or ”the Company”) rights issue of shares, with the subscription period ending on April 12th, 2023, has now been registered with the Swedish Companies Registration Office. The Company hereby announces that the last day for trading with BTA (paid subscribed shares) will be May 3rd, 2023, and the stop day will be May 5th, 2023.

Stayble Therapeutics AB (“Stayble” or the “Company”) announces that the Company has strengthened its scientific advisory board with Professor Daisuke Sakai, MD, PhD, as new scientific advisor. Dr Sakai will bring experience from the Japanese perspective in the field of treating degenerative disc disease as well as herniated discs. His broad knowledge in the field will strengthen our current scientific advisory board.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, RUSSIA, BELARUS OR IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION OR WOULD REQUITE FURTHER REGISTRATION OR OTHER MEASURES ABOVE WHAT IS REQUIRED BY SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.

NB: This is an English convenience translation of this press release. In case of any discrepancy, the correct version is the Swedish original “Stayble Therapeutics AB genomför kvittningsemission för garanter I samband med den avslutade företrädesemissionen”.

Stayble Therapeutics AB (”Stayble” or ”the Company”) has concluded the rights issue of shares, which was decided on by the Board of Directors on February 22nd, 2023, and which was confirmed by an extraordinary general meeting on March 16th,  2023 (“the Rights Issue”).  In connection with this, a directed offset issue of shares is implemented for the underwriters who have chosen to receive remuneration in the form of newly issued shares in the Company (”the Remuneration Issue”), according to the underwriting commitments entered into as part of the Rights Issue and as previously communicated. The subscription price of the Remuneration Issue is set to SEK 1.78 per share (equal to the set subscription price of the concluded Rights Issue) and payment will be made in the form of an offset by the underwriter’s claim of remuneration.

Stayble Therapeutics AB (”Stayble” or ”the Company”) today announces that Jarkko Kalliomäki will assume the role of Chief Medical Officer (CMO) in the Company. Jarkko Kalliomäki is a specialist physician in rehabilitation and pain management and a medical doctor in physiology. He has over ten years of experience in the pharmaceutical industry in a number of pain-related projects and works as a senior physician in rehabilitation medicine and pain management at, among others, Lunds Universitetssjukhus Sophiahemmet and Capio S:t Göran’s hospital, Stockholm.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, RUSSIA, BELARUS OR IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION OR WOULD REQUITE FURTHER REGISTRATION OR OTHER MEASURES ABOVE WHAT IS REQUIRED BY SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.

NB: This is an English convenience translation of this press release. In case of any discrepancy, the correct version is the Swedish original “Stayble Therapeutics AB offentliggör utfall i genomförd företrädesemission”.

The subscription period of Stayble Therapeutic AB’s (“Stayble” or “the Company”) preferential rights issue of shares, in which the public was also given the opportunity to subscribe, was concluded on April 12th, 2023. The rights issue was subscribed to a total of approximately 90 percent, including pre-subscription and underwriting commitments. Stayble will therefore be provided approximately MSEK 31.7 before transaction related costs. The formal decision of allocation and mailing of settlement notes are planned to take place around April 14, 2023.

Stayble Therapeutics AB (”Stayble” or the ”Company”) is currently conducting a phase 2b study with the drug candidate STA363. The Company now presents positive interim data with established safety and tolerability as well as lower dispersion in pain measurements when analyzing now available blinded data from the six-month follow-up in the study.

In connection with the ongoing rights issue, Stayble Therapeutics CEO Andreas Gerward makes a number of presentations and interviews. More information about the rights issue, where the subscription period runs until 12 April, see https://www.foretradesemission.staybletherapeutics.se/.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, RUSSIA, BELARUS OR IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION OR WOULD REQUITE FURTHER REGISTRATION OR OTHER MEASURES ABOVE WHAT IS REQUIRED BY SWEDISH LAW. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.

NB: This is an English convenience translation of this press release. In case of any discrepancy, the correct version is the Swedish original “Stayble Therapeutics AB offentliggör tilläggsprospekt med anledning av företrädesemissionen”. 

The Board of Directors of Stayble Therapeutics AB (”Stayble” or ”the Company”) has established a supplement (“the Supplementary Prospectus”) to the EU Growth Prospectus published on March 17th, 2023 (“the Prospectus”. The Supplementary Prospectus has today been approved and registered by the Swedish Financial Supervisory Authority.